IDENTIFICATION OF RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-![]() |
Ha, Woo-Hun
(Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University)
Hwang, Dae-Seok (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) Kim, Yong-Deok (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) Shin, Sang-Hun (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) Kim, Uk-Kyu (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) Kim, Jong-Ryoul (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) Chung, In-Kyo (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) |
1 | Wttrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Redini F: RANKL/RANK/OPG: new therapeutic targets in bone tumors and associated osteolysis. Bioch et Biophys Acta 2004;1704:49-57 |
2 | Guise TA, Mundy GR: Cancer and bone. Endocr. Rev. 1998;19:18- 54 DOI ScienceOn |
3 | Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D: RANKL/OPG ratio in increased in severe osteolysis. Am J Pathol 2003;163:2021-31 DOI ScienceOn |
4 | Lacey DL, Timms E, Tan HL, Kelly MJ, Dunstan CR, Burgess T, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76 DOI ScienceOn |
5 | Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, et al: Transforming growth factor-beta stimulates the production of osteoprotegerin/ osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998;273:27091-6 DOI ScienceOn |
6 | Good CR, O'Keefe RJ, Puzas JE, Schwarz EM, Rosier RN: Immunohistochemical study of RANKL in human osteolytic bone tumors. J Surg Oncol 2002;79:174-9 DOI ScienceOn |
7 | Wise GE, Lumpkin SJ, Huang H, Zhang Q: Osteoprotegerin and osteoclst differentiation factor in tooth eruption. J Dent Res 2000;79:1937-42 DOI ScienceOn |
8 | Horowizt MC, Xi Y, Wilson K, Kacena MA: Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001;12:9-18 DOI ScienceOn |
9 | Miyamoto T, Ohneda O, Arai F, Iwamoto K, Okada S, Takagi K, et al: Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001;98:2544-2554 DOI ScienceOn |
10 | Khanna S, Khanna NN: Predicting recurrence in the mandibular and maxillary ameloblastoma. Ear Nose Throat J 1978;57:56 |
11 | Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuchi SI, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602?쳘 |
12 | Hofbauer LC, Gori F, Rigg BL, Lacey LD, Dunstan DR, Spielsberg TC, et al: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoid in human osteoblastic lineage cells: potential paracrine mechanism of glucocorticoid induced osteoporosis. Endocrinology 1999;140:4382-9 DOI ScienceOn |
13 | Tay JYY, Bay BH, Yeo JF, Harris M, Meghji S, Dheen ST: Identification of RANKL in osteolytic lesions of the facial skeleton. J Dent Res 2004;83:349-53 DOI ScienceOn |
14 | Kitazawa R, Kitazawa S, Maeda S: Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Boichem Biophys Acta 1999;1445:134-41 DOI ScienceOn |
15 | Gardner DC: Controversies in the nomenclature, diagnosis and treatment of ameloblastoma. Controversies in Oral and maxillofacial Surgery. Philadelphia, W.B Saunders, 1994, 301 |
16 | Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russel GR, Van Camp B, Vanderkerken K: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-40 DOI ScienceOn |
17 | O'Brien EA, Williams JH, Marshall MJ: Osteoprotegerin ligand regulates osteoclast adherence to the bone surface of mouse calvaria. Biochem Biophys Res Commun 2000;274:281-90 DOI ScienceOn |
18 | Tsuda E, Goto M, Michizuki S, Yano K, Kobayashi F, Morinaga T, Hisgashio K: Isolation of a novel cytokine from human fibroblast that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-42 DOI ScienceOn |
19 | Wong BG, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4 DOI ScienceOn |
20 | Zhang Dai J, Qi Y, Lin D.L, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET: Osteoprotegerin inhibits prostate cancerinduced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44 DOI ScienceOn |
21 | Hartman Ks: Granular cell ameloblastoma. Oral Surg Oral Med Oral Pathol 1974;38:241 DOI ScienceOn |
22 | Lee SK, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-61 DOI ScienceOn |
23 | Nagai M, Kyakumoto S, Sato N: Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 2000;269:532-6 DOI ScienceOn |
24 | Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin. a novel secreted protein involved in the regulation of bone densty. Cell 1997;89:309-19 DOI ScienceOn |
25 | Kawamoto S, Ejiri S, Hoshi K, Nahaoka E, Ozawa H: Immunolocalization of osteoclast differentiation factor in rat periodontium. Arch Oral Biol 2002;47:55-58 DOI ScienceOn |
26 | Barns L: Surgical pathology of the head and neck. New York, Marcel Dekker. 1986, 1332 |
27 | Neville, Damm, Allen, Bouquot: Oral and maxillofacial pathology. Philadelphia, W.B. Saunders Co. 2002, 611-9 |
28 | Takahashi N, Akatsu T, Saaki T, Yamaguchi A, Moseley JM, Martin TJ, et al: Osteoclastic cells are involved in osteoclast formation. Endocrinology 1998;123:2600-2 |
29 | Fuller K, Wong B, Fox S, Choi Y, Chambers TJ: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001 DOI |
30 | Lacey DL, Timms E, Tan HL, Kelly MJ, Dunstan CR, Burgess T, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76 DOI ScienceOn |
31 | Rani CSS, MacDougall M: Dental cells express factors that regulate bone resorption. Mol Cell Biol Res Comm 2000;3:145-52 DOI ScienceOn |
32 | Hiroyuki K, Kiyoshi O: Expression of PTHrP, ODF/RANKL and OCIF/OPG in ameloblastoma. J Oral Pathol Med 2004;33:46-52 DOI ScienceOn |
33 | Wong BG, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4 DOI ScienceOn |
34 | Piattelli A, Fioroni M, Santinelli A, Rubini C: Expression of proliferating cell nuclear antigen in ameloblastoma and odontogenic cysts. Oral Oncology 1998;34:408-12 DOI ScienceOn |
35 | Jimi E, Nakamura I, Amano H, Taguchi Y, Tsurukai T, Tamura M, et al: Osteoclast function is activated by osteoclastic cells through a mechanism involving cell-to-cell contact. Endocrinology 1997;137:2187-90 |
36 | Rousselle AV, Heymann D: Osteoclastic acidication during bone resorption. Bone 2002;30:533-40 DOI ScienceOn |
![]() |